Stockreport

NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial [Yahoo! Finance]

NanoViricides, Inc.  (NNVC) 
NASDAQ:AMEX Investor Relations: nanoviricides.com/investorinfo.html
PDF NanoViricides (NYSE-A:NNVC) said on Wednesday it has completed manufacturing of its NV-387 oral drug product, clearing a key step toward dosing patients in an upcoming [Read more]